These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31185226)

  • 1. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
    Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
    Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of miR-34a-5p, miR-20a-3p and miR-29a-3p by Onconase in A375 Melanoma Cells Correlates with the Downregulation of Specific Onco-Proteins.
    De Tomi E; Campagnari R; Orlandi E; Cardile A; Zanrè V; Menegazzi M; Gomez-Lira M; Gotte G
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
    Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
    Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
    Oplustil O'Connor L; Rulten SL; Cranston AN; Odedra R; Brown H; Jaspers JE; Jones L; Knights C; Evers B; Ting A; Bradbury RH; Pajic M; Rottenberg S; Jonkers J; Rudge D; Martin NM; Caldecott KW; Lau A; O'Connor MJ
    Cancer Res; 2016 Oct; 76(20):6084-6094. PubMed ID: 27550455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; Maretto M; Bassetti E; Caiazzo R; D'Orazi G; Cirone M
    Exp Cell Res; 2021 Nov; 408(2):112879. PubMed ID: 34653407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells.
    Sargazi S; Saravani R; Zavar Reza J; Zarei Jaliani H; Galavi H; Moudi M; Abtahi NA
    Iran Biomed J; 2019 Sep; 23(5):312-23. PubMed ID: 31102368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
    Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
    Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
    Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    Weigert V; Jost T; Hecht M; Knippertz I; Heinzerling L; Fietkau R; Distel LV
    BMC Cancer; 2020 Aug; 20(1):775. PubMed ID: 32811446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
    Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
    EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
    Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
    Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.